Evolution of breast cancer treatments: current options and quality-of-life considerations
- 1 January 2004
- journal article
- research article
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 8, S75-S82
- https://doi.org/10.1016/j.ejon.2004.09.005
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI Journal of the National Cancer Institute, 2003
- Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil–Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists GroupJournal of Clinical Oncology, 2003
- Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapySeminars in Oncology, 2003
- Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast CancerBreast Cancer Research and Treatment, 2002
- The impact of endocrine therapy on patients with breast cancer: a review of the literatureThe Breast, 2002
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 2001
- Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol AcetateJournal of Clinical Oncology, 2001
- Endocrine therapy in the treatment of metastatic breast cancerSeminars in Oncology, 2001
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- Phase II Evaluation of Lyl56758 in Metastatic Breast CancerOncology, 1988